ReviewDiscover oncology2026
Revealing the promising therapeutic targets and prognostic markers of primary mediastinal large B-cell lymphoma.
Review in Discover oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Primary mediastinal large B-cell lymphoma (PMBCL) is an aggressive B-cell lymphoma, which has been considered to be a separate subtype different from diffuse large B-cell lymphoma (DLBCL). PMBCL has unique molecular signatures characterized by the activation of JAK-STAT and NF-κB pathways, which are more similar to classical Hodgkin's lymphoma (cHL). Moreover, the immune-privileged phenotype is predominant, which is achieved by a series of genetic alterations. Most patients have a superior response to initial therapies, but there are still some patients with relapsed/refractory (R/R) disease. Novel therapies targeting potential therapeutic targets underlying the molecular pathogenesis may improve the outcomes of R/R patients. Additionally, abundant research indicated that PET-CT radiomics and some clinical features were significantly correlated with PMBCL prognosis. The role of consolidative radiotherapy remains controversial. More accurate prognostic-models based on PET radiomics and related clinical features are required to provide precise risk-stratification and guide subsequent treatment choices for PMBCL patients.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.